P. Petteruti

Most-cited papers

1. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

   G. Rhyasen, M. Hattersley, Yi Yao, A. Dulak +25 more

   2016Molecular Cancer Therapeutics132 citations Open access

   Semantic Scholar

   Save

2. Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6.

   W. McCoull, Tony Cheung, Erica K. Anderson, Peter Barton +33 more

   2018ACS Chemical Biology121 citations Open access

   Semantic Scholar

   Save

3. Potent and selective bivalent inhibitors of BET bromodomains.

   M. Waring, Huawei Chen, A. Rabow, Graeme E. Walker +26 more

   2016Nature Chemical Biology120 citations Open access

   Semantic Scholar

   Save

4. Discovery and mechanistic study of a small molecule inhibitor for motor protein KIFC1.

   Jiaquan Wu, K. Mikule, Wenxian Wang, Nancy Su +11 more

   2013ACS Chemical Biology116 citations

   Semantic Scholar

   Save

5. Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering.

   J. Johannes, L. Almeida, K. Daly, A. Ferguson +23 more

   2015Bioorganic & Medicinal Chemistry Letters56 citations Open access

   Semantic Scholar

   Save

6. MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo

   D. Jenkins, Sarah J. Ross, Margaret H Veldman-Jones, I. Foltz +14 more

   2012Molecular Cancer Therapeutics55 citations

   Semantic Scholar

   Save

7. Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer.

   Ze-Bin Wang, S. Grosskurth, Tony Cheung, P. Petteruti +21 more

   2018Cancer Research40 citations Open access

   Semantic Scholar

   Save

8. Structure-Guided Design and In-Cell Target Profiling of a Cell-Active Target Engagement Probe for PARP Inhibitors

   Ryan T. Howard, P. Hemsley, P. Petteruti, Charlie N. Saunders +4 more

   2020ACS Chemical Biology22 citations Open access

   Semantic Scholar

   Save

9. Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors

   Tammie C. Yeh, G. O'Connor, P. Petteruti, A. Dulak +3 more

   2017Clinical Cancer Research22 citations Open access

   Semantic Scholar

   Save

10. Abstract 4705: Therapeutic activity of bivalent BRD4 inhibitor AZD5153 in hematological cancers

    Huawei Chen, M. Hattersley, G. Rhyasen, A. Dulak +18 more

    20161 citations

    Semantic Scholar

    Save

11. Bivalent binding to BET bromodomains

    M. Waring, Hong-Min Chen, A. Rabow, Graeme E. Walker +20 more

    20161 citations

    Semantic Scholar

    Save

12. Abstract A134: Functional perturbation of PARP6 affects centromeric proteins and is associated with increased multi-polar spindles in breast cancer cell lines.

    S. Grosskurth, P. Petteruti, Xin Wang, K. Mikule

    20131 citations

    Semantic Scholar

    Save

13. Abstract A221: Novel PARP6 inhibitors demonstrate in vivo efficacy in xenograft models.

    M. Mayo, S. Grosskurth, Xin Wang, P. Petteruti +3 more

    20131 citations

    Semantic Scholar

    Save

14. Development of a novel BCL6 PROTAC to provide insight into small molecule targeting of BCL6

    W. McCoull, Tony Cheung, Erica K. Anderson, Peter Barton +37 more

    20180 citations

    Semantic Scholar

    Save

15. Abstract C55: Discovery and optimization of inhibitors of the KIFC1 motor protein.

    M. Lamb, Jiaquan Wu, K. Mikule, Wendy Wang +14 more

    20130 citations

    Semantic Scholar

    Save

16. of Tissue Factor Pathway Inhibitor Shear Stress Decreases Endothelial Cell Tissue Factor Activity by Augmenting Secretion

    E. Grabowski, A. Reininger, P. Petteruti, O. Tsukurov +1 more

    20000 citations

    Semantic Scholar

    Save